The exclusive agreement with Zelthy will help drive DKSH’s portfolio of patient access and support programs in 14 Asian markets.

Bangkok, March 13, 2020 – DKSH Business Unit Healthcare, Asia’s leading partner for healthcare companies seeking to grow their business in Asia, has entered into an exclusive partnership in Asia with Bangalore-based health cloud start-up Zelthy. The company will help to roll out DKSH’s patient access and support programs in 14 Asian markets in total, including Thailand, Malaysia, Brunei, Singapore, Vietnam, Indonesia, the Philippines, Cambodia, Myanmar, Laos, Hong Kong, Macau, Taiwan and South Korea. Zelthy’s state-of-the-art “Software as a Service” (SaaS) platform allows the support of multiple programs around access, education, assistance and therapy initiation. Zelthy Cloud currently hosts numerous programs on some of the largest global blockbuster drugs and touches the lives of over 200,000 patients in India.

Zelthy’s cloud-based digital platform will allow DKSH to execute patient access and support programs for pharmaceutical and medical device clients with full control over patient management, benefits management and distribution management. TheDKSH Patient Support Program (PSP) Cloud, powered by Zelthy, complies with the security and privacy requirements defined by the Health Insurance Portability and Accountability Act (HIPAA), the industry’s standards agency. The integrated platform allows stakeholders, including patients, healthcare personnel, health insurers, lab managers as well as DKSH’s call centers and distribution centers, to manage access, education adherence and convenience programs to provide patients with the support they need beyond just their drug treatment.

Anshuman Chaudhary, Co-founder and Head Commercial of Zelthy, said: “We are excited to become part of DKSH’s extensive network of partners across Asia. We believe that our platform can make a difference in the lives of patients and that we can support the healthcare ecosystem to meet the needs of patients across the patient journey.”

Bijay Singh, Global Head Business Unit Healthcare, DKSH, stated: “Our strategic purpose is to enrich the lives of Asian people by providing access to quality healthcare. The patient is at the center of the healthcare ecosystem, so we are particularly pleased to join with Zelthy in taking the next step in offering meaningful patient support programs to improve access adherence to treatment and clinical outcomes. Quality and compliance are cornerstones of our approach at DKSH. The DKSH Patient Support Program (PSP) Cloud, powered by Zelthy, complies with security and privacy requirements defined by HIPAA, the industry’s standards agency. Patient solutions is one of several key value-added services from DKSH, designed with the needs of Asian clients, customers and patients.”

About Zelthy

Zelthy is cloud platform used by global pharmaceutical companies and healthcare organizations. Its proprietary framework and data models support quick setup of patient program applications hosted in a secured cloud environment. Multiple initiatives around access, assistance, support, therapy initiation, etc. are supported on the Zelthy platform. Zelthy currently hosts multiple programs on some of largest global blockbuster drugs and touches the lives of over 200,000 patients.

About DKSH

DKSH is the leading Market Expansion Services provider with a focus on Asia. The Group helps companies to grow across the Business Units Healthcare, Consumer Goods, Performance Materials and Technology. The service portfolio covers sourcing, market insights, marketing and sales, eCommerce, distribution and logistics as well as after-sales services. Publicly listed on the SIX Swiss Exchange, the Group operates in 36 markets with 33,350 specialists, generating net sales of CHF 11.6 billion in 2019. With its Swiss heritage, DKSH has been deeply rooted in Asia Pacific since 1865. The DKSH Business Unit Healthcare distributes pharmaceuticals, consumer health and overt-the-counter (OTC) products as well as medical devices. With around 8,220 specialists, the Business Unit generated net sales of CHF 6.0 billion in 2019.